Celgene Amends its Existing Collaboration with Editas to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for Cancer and Autoimmune Diseases

Celgene Collaborates with Exscientia for its AI Drug Discovery Platform


  • Editas to receive $70M up front, milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in to such genome editing tools for the development of gene-edited alpha-beta T cell therapies
  • In May’2015, Editas and Juno entered into an exclusive collaboration to develop CAR T and TCR Cell Therapies, under which Editas has received $25M as upfront & ~$22M to support research over the next five years across the three programs in the alliance along with $230M research, regulatory, and commercial milestones and royalties for each program
  • The amended agreement replaces the original agreement, allowing Editas to develop non-alpha-beta T cell therapies while expanding Celgene’s access to gene-edited alpha-beta T cells beyond oncology

Click here to­ read full press release/ article | Ref: Editas  | Image: The Boston Globe